The local PI(4,5)P2 nanodomain promotes the dimerization and activation of EGFR in the plasma membrane, whereas activated EGFR dissolves the nanodomain structure of PI(4,5)P2 through PLCγ.
Cryo-EM analysis of full-length human epidermal growth factor receptor provides a molecular explanation for how ligand-induced differential effect in the ligand-binding extracellular module tunes the transmembrane signaling mediated by epidermal growth factor receptor.
Ioannis Galdadas, Luca Carlino ... Francesco Luigi Gervasio
Computational methods reveal how mutations affect the conformational landscape of the kinase domain of EGFR resulting in abnormal signaling and provide a structural framework for ongoing drug discovery efforts on mutant-specific EGFR inhibition.
Nicolás Peláez, Arnau Gavalda-Miralles ... Richard W Carthew
The maturation of multi-potent immature cells in the larval eye in Drosophila is regulated by a transcription factor that displays unexpected heterogeneous dynamics during the cells’ transitions towards differentiated states.
Stéphanie Torrino, Victor Tiroille ... Stephan Clavel
UBTD1 coordinates EGFR signaling by modulating ceramides level through ASAH1 ubiquitination and EGFR degradation through SQSTM1/p62 ubiquitination, which together impact cell proliferation.
Mathematical methods based on geometry that directly embody the developmental concepts of competency, commitment, and determination provide succinct descriptions of morphogenesis and allow quantitative predictions from fits to sparse genetic data in Caenorhabditis elegans.
Payam E Farahani, Xiaoyu Yang ... Jared E Toettcher
pYtags are novel biosensors that can be used to measure the activity of a receptor tyrosine kinase of interest in live cells with high spatiotemporal resolution and are applied to reveal rapid activity dynamics of EGFR/ErbB2 signaling.
Biochemical approaches and cellular experiments show a novel effect of METTL3 on homologous recombination repair and chemotherapeutic response via the m6A-YTHDC1-dependent regulation of the EGF/RAD51 axis.
Tailoring Boolean models to 488 prostate cancer patients and 8 cell lines data allows for the experimentally validated personalisation of drug treatments.
